Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment

Spencer, Charles T.; Beevers, D. G.; Lip, Gregory Y.H.

doi:10.1038/sj.jhh.1001085

Cited by 6 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial hypertension is accompanied by vascular complications associated with platelet activation and endo-thelium damage. 1,2 They can contribute to the processes of atherogenesis and intravascular thrombosis. Plasma ␤-thromboglobulin is an established marker of platelet activity, whilst von Willebrand factor (vWF) and soluble thrombomodulin are used to assess the endothelium integrity.…”

Section: Introductionmentioning

confidence: 99%

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Remková

Kratochvílová

2002

J Hum Hypertens

View full text Add to dashboard Cite

The aim of the study was to investigate the effect of therapy by rilmenidine on endothelial and platelet function in 23 patients with the early stages of untreated essential hypertension. The measurements were carried out before therapy, after 1 week of placebo administration, after 1 week, after 1 month and after 3 months of therapy. After 1 week of therapy both systolic (SBP) and diastolic blood pressure (DBP) were reduced (P Ͻ 0.001) all over the study period. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, and plasma ␤-thromboglobulin (␤TG) as an indicator of in vivo platelet activation, were investigated. Fibrinogen as a risk factor for vascular changes was also assayed. Platelet aggregation without stimulation (spontaneous, SPA) and induced by adre-

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Remková

Kratochvílová

2002

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…There is also an interesting observation that satisfactory BP reduction with various kinds of antihypertensive drugs may not lead to an identical reduction in stroke patients, so it is inferred that this observation may partly be due to the unsatisfactory effects of some drugs in hemorheology. 40 Furthermore, epidemiological studies have found an increased risk of cardiovascular disease in patients with higher mean blood viscosity levels, but it is not relevant to whether they belong to hypertensive or normotensive individuals. 41 So hemorheological change might play a more important role in stroke patients.…”

Section: Discussionmentioning

confidence: 99%

IMM-H004, a coumarin derivative, attenuated brain ischemia/reperfusion injuries and subsequent inflammation in spontaneously hypertensive rats through inhibition of VCAM-1

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The study was conducted as a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT), which compared antihypertensive regimens based on either a β‐blocker with the addition of a diuretic or a calcium antagonist with the addition of an angiotensin converting enzyme inhibitor [18, 19]. In addition, subjects with a total cholesterol of less than 6.5 mmol L −1 were randomized to receive the cholesterol‐lowering drug atorvastatin, or placebo.…”

Section: Methodsmentioning

confidence: 99%

Platelet and haemorheological markers in ‘high risk’ hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT)

Spencer

Gurney

Felmeden

et al. 2003

Journal of Internal Medicine

View full text Add to dashboard Cite

Abstract. Spencer CGC, Gurney D, Felmeden DC, Blann AD, Beevers DG, Lip GYH (City Hospital, Birmingham, UK). Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the AngloScandinavian Cardiac Outcomes Trial (ASCOT). Objective. To investigate the impact of intensified cardiovascular risk management on soluble markers of platelet, endothelial and rheological function in a population of middle-aged hypertensive patients at high risk of cardiovascular complications. Design. Prospective follow-up study. Subjects and methods. A total of 159 hypertensive patients [138 male, mean age 64 (±8) years] and 80 healthy controls were studied. Plasma levels of soluble P-selectin (sP-sel, a marker of platelet function), von Willebrand factor (vWF, an index of endothelial damage/dysfunction) and rheological indices [fibrinogen (Fib), plasma viscosity (PV), haematocrit (HCT), white blood count (WBC) and platelet count] were measured at baseline and again (in the patients) after 6 months' treatment.Results. As expected, 6 months of intensified cardiovascular risk management resulted in a significant fall in mean blood pressure (BP) and total cholesterol. It also resulted in reduced haematocrit, vWF, sP-sel, WBC and PV levels (all P < 0.001), but not plasma fibrinogen. There were no correlations between the fall in BP and the improvement in any of the research indices. Conclusions. Intensified cardiovascular risk management results in significant improvements in indices of endothelial, platelet and rheological function in a population of hypertensives at high risk of cardiovascular events. These improvements appear to be independent of the degree of change in BP. Given the fundamental role of interactions between the endothelium and circulating blood components in the pathogenesis of hypertensive complications this may be of importance in preventing adverse cardiovascular outcomes.

show abstract

Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment

Cited by 6 publications

References 20 publications

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

IMM-H004, a coumarin derivative, attenuated brain ischemia/reperfusion injuries and subsequent inflammation in spontaneously hypertensive rats through inhibition of VCAM-1

Platelet and haemorheological markers in ‘high risk’ hypertensives are improved by tighter blood pressure control and cardiovascular risk management: a substudy of the Anglo‐Scandinavian Cardiac Outcomes Trial (ASCOT)

Contact Info

Product

Resources

About